company background image
1U5 logo

Wave Life Sciences DB:1U5 Stock Report

Last Price

€11.60

Market Cap

€1.8b

7D

4.5%

1Y

215.2%

Updated

06 Feb, 2025

Data

Company Financials +

Wave Life Sciences Ltd.

DB:1U5 Stock Report

Market Cap: €1.8b

1U5 Stock Overview

A clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. More details

1U5 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 42.09% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Volatile share price over the past 3 months compared to the German market


My Notes

Capture your thoughts, links and company narrative

Wave Life Sciences Ltd. Competitors

Dermapharm Holding

XTRA:DMP

€2.1b

PharmaSGP Holding

XTRA:PSG

€333.3m

Bayer

XTRA:BAYN

€20.8b

MPH Health Care

DB:93M1

€96.8m

Price History & Performance

Summary of share price highs, lows and changes for Wave Life Sciences
Historical stock prices
Current Share PriceUS$11.60
52 Week HighUS$15.70
52 Week LowUS$3.28
Beta-1.1
1 Month Change-5.69%
3 Month Change-15.33%
1 Year Change215.22%
3 Year Change446.65%
5 Year Change63.38%
Change since IPO-67.33%

Recent News & Updates

Recent updates

Shareholder Returns

1U5DE PharmaceuticalsDE Market
7D4.5%-5.2%0.5%
1Y215.2%-10.6%15.3%

Return vs Industry: 1U5 exceeded the German Pharmaceuticals industry which returned -11.7% over the past year.

Return vs Market: 1U5 exceeded the German Market which returned 13.7% over the past year.

Price Volatility

Is 1U5's price volatile compared to industry and market?
1U5 volatility
1U5 Average Weekly Movement9.3%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 1U5's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 1U5's weekly volatility has decreased from 16% to 9% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2012267Paul B. Bolnowww.wavelifesciences.com

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington’s disease (HD).

Wave Life Sciences Ltd. Fundamentals Summary

How do Wave Life Sciences's earnings and revenue compare to its market cap?
1U5 fundamental statistics
Market cap€1.80b
Earnings (TTM)-€137.20m
Revenue (TTM)€51.61m

33.7x

P/S Ratio

-12.7x

P/E Ratio

Is 1U5 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1U5 income statement (TTM)
RevenueUS$53.61m
Cost of RevenueUS$149.11m
Gross Profit-US$95.50m
Other ExpensesUS$47.02m
Earnings-US$142.52m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.93
Gross Margin-178.14%
Net Profit Margin-265.84%
Debt/Equity Ratio0%

How did 1U5 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 10:25
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Wave Life Sciences Ltd. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madison Wynne El-SaadiB. Riley Securities, Inc.
Steven SeedhouseCGS International
Whitney IjemGuggenheim Securities, LLC